Immunomodulating activity of myelopeptides: clinical trials.
Bone marrow cells of various animal species and the human produce a group of bioregulatory peptides called myelopeptides (MPs). A highly purified myelopeptide (MP) fraction and some individual molecules have been isolated from the supernatant of the porcine bone marrow cell culture by successive gel chromatography and HPLC. Myelopeptides have a wide spectrum of functions including immunoregulatory, differentiating, and opiate-like activities. A new immunoreactive drug, Myelopidum, has been created on the basis of myelopeptides. This drug is effectively used in Russian medicine for treating diseases accompanied by immunodeficiency and in veterinary practice for prophylaxis and treatment of newborn and young animals with such diseases as pneumonia and enteritis. Treatment of patients by Myelopidum after major surgery prevents 50 to 70 percent of postsurgical complications, particularly postsurgical pneumonia. Myelopidum normalizes the number and balance of T helper and T suppressor cells and B lymphocytes in patients with chronic pulmonary diseases and promotes the beneficial clinical effect of significant prolongation of periods of remission.
Petrov
R V
RV
Ministry of Health, Institute of Immunology, Moscow, Russia.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D002986:Clinical Trials as Topic; D006801:Humans; D009842:Oligopeptides; D010455:Peptides / Q000494:pharmacology / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D009842:Oligopeptides; D010455:Peptides; C048617:myelopeptides